A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)

NCT00989001 | Terminated Phase 3 DMC

• 3 other identifiers: 6621-0456517-CL-0020MK-6621-045
• Study Type: interventional
• Target: 217
• Locations: 0 countries
• Sites: N/A

Brief Summary

The purpose of this study is to evaluate the safety and efficacy of vernakalant injection in subjects with recent onset (AF \> 3 hours to \<= 7 days), symptomatic atrial fibrillation and no evidence or history of congestive heart failure.

Conditions

Atrial Fibrillation

Keywords

Atrial Fibrillation; RSD1235; Vernakalant; conversion

Outcome Measures

Primary Outcomes (2)

• Number of Participants who Experience Hypotension, Ventricular Arrhythmias and/or Death

  Hypotension defined as: systolic blood pressure (SBP) \<90 mmHg and treated with pressors; SBP \<90 mmHg and treated with albumin, dextran or hydroxyethyl starch; or SBP \<90 mmHg and seizures. Ventricular arrhythmias defined as: Sustained ventricular tachycardia with a heart rate of \>120 beats per minute. Sustained tachycardia defined as lasting \>30 seconds; Torsade de Pointes with a duration of \>10 seconds; Ventricular fibrillation of any duration.

  Occurring within the first two hours after start of study treatment

• Number of Participant with Successful Conversion to Sinus rhythm (SR)

  Successful conversion defined as return to sinus rhythm for at least 1 minute documented by Holter electrocardiogram (ECG) or by two consecutive 12-lead ECGs recorded \> 1 minute apart within 90 minutes of first exposure to study treatment

  Occurring within 90 minutes of first exposure to study treatment

Secondary Outcomes (2)

• Time from First Exposure to Study Treatment to Conversion of AF to SR

  Occurring within 90 minutes after study treatment

• Number of Participants who Report No Symptoms

  Occurring 90 minutes after first exposure to study treatment

Study Arms (2)

Vernakalant

EXPERIMENTAL

Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes

Drug: Vernakalant

Placebo

PLACEBO COMPARATOR

Placebo (saline) administered IV at same volume and rate as per dosing schedule for vernakalant

Drug: Placebo

Interventions

Vernakalant DRUG

Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes

Also known as: RSD1235

Vernakalant

Placebo DRUG

Injection

Placebo

Eligibility Criteria

• Age: 18 Years - 85 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Females must be not pregnant or nursing and if pre-menopausal, must be using an effective form of birth control from time of screening until 30 days post study treatment
• Subject must have recent onset (\> 3 hours to \<= 7 days) symptomatic AF to be best managed by acute conversion to SR
• Subject must have adequate anticoagulant therapy
• Subject must have systolic blood pressure (SBP) above 90 mmHg and less than 160 mmHg and diastolic blood pressure (DBP) less than 95 mmHg at screening and baseline
• Subject must have a body weight between 45 and 136 kg, inclusive (99 and 300 lbs)

You may not qualify if:

• Subject has a history of heart failure or documentation of left ventricular dysfunction
• Subject has known or suspected prolonged QT or uncorrected QT interval of \> 0.440 sec
• Subject has symptomatic bradycardia or ventricular rate less than 50 bpm at Screening, unless controlled by a pacemaker
• Subject has bradycardia (heart rate less than 50 bpm) or hypotension (SBP less that 90 mmHg) after receiving a loading, bolus dose, or sustained infusion of any rate control medication during Screening
• Subject has a QRS interval \> 0.14 sec., unless subject has a pacemaker
• Subject had a myocardial infarction (MI), acute coronary syndrome, cardiac surgery (including percutaneous transluminal coronary angioplasty (PTCA) or stent placement), within 30 days prior to enrollment or subject has evidence of new ischemic changes on Screening 12-lead ECG
• Subject has troponin I or T levels beyond the upper limit of normal for the local lab
• Subject has significant valvular stenosis, hypertrophic obstructive cardiomyopathy, restrictive cardiomyopathy or constrictive pericarditis
• Subject has failed electrical cardioversion for AF at anytime
• Subject has failed pharmacologic conversion with an intravenous Class I or Class III antiarrhythmic drug for this episode of AF
• Subject has any known reversible causes of AF such as alcohol intoxication, pulmonary embolism, hyperthyroidism, acute pericarditis or hypoxemia
• Subject has uncorrected electrolyte imbalance
• Subject has clinical evidence of digoxin toxicity
• Subject has a history of clinically significant illness (e.g. neurological, gastrointestinal, renal, hepatic, pulmonary, metabolic, endocrine, hematological, or psychiatric), medical condition or laboratory abnormality within 4 weeks prior to Screening

Sponsors & Collaborators

• Advanz Pharma: lead

Related Publications (1)

• Beatch GN, Mangal B. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial. BMC Cardiovasc Disord. 2016 May 28;16:113. doi: 10.1186/s12872-016-0289-0.

  PMID: 27233239 DERIVED

MeSH Terms

Conditions

Atrial Fibrillation

Interventions

vernakalant

Condition Hierarchy (Ancestors)

Arrhythmias, Cardiac; Heart Diseases; Cardiovascular Diseases; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: October 1, 2009
• First Posted: October 2, 2009
• Study Start: October 1, 2009
• Primary Completion: November 1, 2010
• Study Completion: November 1, 2010
• Last Updated: March 10, 2014

Record last verified: 2014-02